Kenvue Inc. shares advanced for a second consecutive session on Wednesday, adding 1.7% to reach $18.72, as the consumer health company continues to trade at a discount relative to Kimberly-Clark's pending cash-and-stock acquisition offer. The stock's gain follows a 3.1% rise in the prior session, reflecting ongoing investor interest in the deal dynamics.
The transaction, valued at approximately $19.11 per Kenvue share based on Kimberly-Clark's latest closing price of $106.71, represents a premium that has narrowed to roughly 2%. Kimberly-Clark shares also rose 2.7% on Wednesday, while consumer health peer Haleon gained 3.2%.
Under the terms of the agreement, Kenvue shareholders will receive $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share held. The deal spread, which measures the gap between Kenvue's market price and the offer's current value, has tightened as both stocks moved in tandem.
Kenvue's recent financial performance has provided some support for the stock. In May, the company reported first-quarter net sales growth of 4.5% year-over-year, with organic sales—excluding currency fluctuations and acquisition effects—rising 0.7%. Diluted earnings per share improved to $0.25 from $0.17 in the prior-year period. Chief Executive Kirk Perry characterized the start of 2026 as "encouraging," though the company refrained from issuing formal guidance due to the pending merger.
RBC Capital Markets analyst Nik Modi noted that the first-quarter results were constructive for Kimberly-Clark, suggesting that "Kenvue's fundamentals appear to be stabilizing," according to Reuters. This stabilization could reduce integration risks for the acquiring company.
However, several uncertainties remain. The transaction, which received approval from both Kenvue and Kimberly-Clark shareholders in January, is expected to close in the second half of 2026, pending regulatory clearances and other customary conditions. Antitrust review processes could introduce delays or require concessions.
Additionally, litigation risks tied to Tylenol, a key Kenvue product, continue to weigh on the deal's perceived value. TD Cowen analyst Robert Moskow cautioned that Kimberly-Clark would assume potential Tylenol-related legal exposure, which "is hard to quantify," as reported by Reuters. Any adverse legal developments could widen the spread or alter the transaction's terms.
Market participants are closely monitoring these factors, as the spread's narrowness suggests confidence in deal completion but also leaves limited room for error. The outcome of regulatory proceedings and any Tylenol lawsuit headlines will likely dictate the stock's near-term trajectory.
